Alexza Inhaled Drug Effective in Study
Posted on: Tuesday, 27 March 2007, 06:00 CDT
Alexza Pharmaceuticals has reported positive initial results from its phase IIa trial of its inhaled drug for acute agitation in schizophrenic patients.
The primary aim of the clinical trial was to assess the safety and efficacy of a single dose of AZ-004 in acutely treating agitation in schizophrenic patients.
In the phase IIa study three doses of the inhaled drug were studied. The 10mg dose of the drug AZ-004 met the primary endpoint of the clinical trial, which was a statistically-significant reduction in the measure of agitation compared to placebo. The lower 5mg dose did not achieve statistical significance. Alexza also said that all three doses significantly reduced migraine pain after two hours compared with placebo
"AZ-004 combines drug delivery speed comparable to that of an intravenous injection, but with the simplicity, convenience and ease of administration of a simple, one-breath inhalation," said Thomas King, president and CEO of Alexza.
Source: Datamonitor
Related Articles
- TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
- Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
- Movetis Advances Cirrhosis Drug to Phase IIb Trial
- Pacgen Announces Positive Results From Phase IIb Dose-Ranging Trial of PAC-113
- Intellect Neurosciences, Inc. Announces the Release of Audited Data for Its Drug Candidate, OXIGON(TM), From a Single Dose Phase I Trial
- Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers' Diarrhea Stimulates Immune Response Even at Low Doses
- Opexa Therapeutics Reports Positive Top-Line Data in Phase I/II Dose Escalation Trial With Tovaxin(TM) for Multiple Sclerosis
- Cell Genesys Launches Expanded Multiple-Dose Phase 1 Trial of CG0070 in Recurrent Bladder Cancer
- Evotec Alzheimer's Drug Well Tolerated in Trial
- ArQule Announces Initiation of Phase 1 Trial With C-Met Inhibitor; First Patient Enrolled and Successfully Dosed In Trial With ARQ 197
User Comments (0)
RSS Feeds